Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ADAP – Adaptimmune Therapeutics plc

Float Short %

3.5

Margin Of Safety %

Put/Call OI Ratio

0.26

EPS Next Q Diff

0.05

EPS Last/This Y

-0.17

EPS This/Next Y

-0.03

Price

0.06

Target Price

0.35

Analyst Recom

3.4

Performance Q

-79.26

Relative Volume

0.9

Beta

2.27

Ticker: ADAP




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25ADAP0.34760.010.023556
2025-07-28ADAP0.1070.010.823644
2025-07-29ADAP0.10350.130.014915
2025-07-30ADAP0.10050.120.005385
2025-07-31ADAP0.08070.120.005476
2025-08-01ADAP0.07990.120.005501
2025-08-04ADAP0.080.110.005674
2025-08-05ADAP0.09510.110.025855
2025-08-06ADAP0.08010.100.766769
2025-08-07ADAP0.08290.111.047017
2025-08-08ADAP0.07740.100.867070
2025-08-11ADAP0.0850.111.097141
2025-08-12ADAP0.07680.120.757313
2025-08-13ADAP0.07820.110.797312
2025-08-14ADAP0.07320.110.037328
2025-08-15ADAP0.05960.116.297523
2025-08-18ADAP0.07130.031.096146
2025-08-19ADAP0.0620.114.497206
2025-08-20ADAP0.0580.17999.997649
2025-08-21ADAP0.05970.2237.707948
2025-08-22ADAP0.05720.266.888246
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25ADAP0.35-156.2- -0.50
2025-07-28ADAP0.10-153.1- -0.50
2025-07-29ADAP0.10-153.1- -0.50
2025-07-30ADAP0.10-153.1- -0.50
2025-07-31ADAP0.08-153.1- -0.50
2025-08-01ADAP0.08-153.1- -0.50
2025-08-04ADAP0.08-153.1- -0.50
2025-08-05ADAP0.10-153.1- -0.50
2025-08-06ADAP0.08-153.1- -0.50
2025-08-07ADAP0.08-153.1- -0.50
2025-08-08ADAP0.08-153.1- -0.50
2025-08-11ADAP0.09-153.1- -0.50
2025-08-12ADAP0.08-153.1- -0.50
2025-08-13ADAP0.08-153.1- -0.50
2025-08-14ADAP0.07-153.1- -0.50
2025-08-15ADAP0.06-153.1- -0.47
2025-08-18ADAP0.07-153.1- -0.47
2025-08-19ADAP0.06-153.1- -0.47
2025-08-20ADAP0.06-153.1- -0.47
2025-08-21ADAP0.06-153.1- -0.47
2025-08-22ADAP0.06-1080.0- -0.47
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25ADAP0.00-23.261.69
2025-07-28ADAP0.00-23.261.69
2025-07-29ADAP0.00-23.261.69
2025-07-30ADAP-69.43-23.261.69
2025-07-31ADAP-69.43-23.261.69
2025-08-01ADAP-69.43-23.261.69
2025-08-04ADAP-69.43-23.301.69
2025-08-05ADAP-69.43-23.301.69
2025-08-06ADAP-69.43-23.301.69
2025-08-07ADAP-69.43-23.301.69
2025-08-08ADAP-69.43-23.301.69
2025-08-11ADAP-69.43-40.421.69
2025-08-12ADAP-69.43-40.423.63
2025-08-13ADAP-69.43-40.423.63
2025-08-14ADAP-69.43-40.423.63
2025-08-15ADAP-68.86-40.423.54
2025-08-18ADAP-68.86-42.993.50
2025-08-19ADAP-70.57-42.993.50
2025-08-20ADAP-75.77-42.993.50
2025-08-21ADAP-75.77-42.993.50
2025-08-22ADAP-75.77-42.993.50
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.11

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

-75.77

Institutional Transactions

-42.99

Beta

2.27

Average Sales Estimate Current Quarter

12

Average Sales Estimate Next Quarter

15

Fair Value

Quality Score

69

Growth Score

41

Sentiment Score

55

Actual DrawDown %

99.5

Max Drawdown 5-Year %

-99.5

Target Price

0.35

P/E

Forward P/E

PEG

P/S

0.23

P/B

P/Free Cash Flow

EPS

-0.66

Average EPS Est. Cur. Y​

-0.47

EPS Next Y. (Est.)

-0.5

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-258.57

Relative Volume

0.9

Return on Equity vs Sector %

214.5

Return on Equity vs Industry %

227.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

Adaptimmune Therapeutics plc
Sector: Healthcare
Industry: Biotechnology
Employees: 506
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
stock quote shares ADAP – Adaptimmune Therapeutics plc Stock Price stock today
news today ADAP – Adaptimmune Therapeutics plc stock forecast ,stock prediction 2023 2024 2025
marketwatch ADAP – Adaptimmune Therapeutics plc yahoo finance google finance
stock history ADAP – Adaptimmune Therapeutics plc invest stock market
stock prices ADAP premarket after hours
ticker ADAP fair value insiders trading